Literature DB >> 2197721

Ophthalmopathy in early thyrotoxicosis--relationship to thyroid receptor antibodies and effects of treatment.

H R Atta1, G McCreath, J H McKillop, J V Forrester, J A Thomson, R Wilson, H W Gray.   

Abstract

A prospective study of 25 newly diagnosed thyrotoxic patients was undertaken to determine the incidence and severity of ophthalmopathy in the early stages of the disease. A quantitative analysis of the ocular muscle changes was made using B scan ultrasonography, and the effects of treatment for the thyroid disease on the course of the eye changes was assessed. Although the majority (75%) of patients showed only mild clinical signs of ophthalmopathy (Werner Class 3 or less), 92% had ultrasonographic evidence of ocular muscle enlargement. Clinical involvement of the extraocular muscles was seen in 12% of the cases. There was an inverse correlation between the serum level of thyroid stimulating hormone receptor antibody (TR Ab) and the size of the extraocular muscles. Recovery of the euthyroid state with treatment was accompanied by a decrease in orbital infiltration in some cases, both clinically (reduced amplitude of intraocular pressure rise on elevation of the globe) and by ultrasonography, but the improvement was not statistically significant.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2197721     DOI: 10.1177/003693309003500203

Source DB:  PubMed          Journal:  Scott Med J        ISSN: 0036-9330            Impact factor:   0.729


  3 in total

1.  Corneal rupture in a child with Down syndrome and hyperthyroidism.

Authors:  Sasha Howard; Joseph Raine; Mehul Dattani
Journal:  BMJ Case Rep       Date:  2009-03-05

2.  Venous stasis orbitopathy: a clinical and echographic study.

Authors:  H R Atta; A D Dick; L M Hamed; S F Byrne; E K Gendron; R L Hughes; J S Glaser
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

3.  Orbital decompression in Graves' ophthalmopathy associated with pretibial myxedema.

Authors:  V Fatourechi; J A Garrity; G B Bartley; E J Bergstralh; C A Gorman
Journal:  J Endocrinol Invest       Date:  1993-06       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.